🇨🇦🏥🥷 Twitterren: "But not to worry: CHECKMATE-227 is hear to save the day! WOW look at those sweet PFS curves... and independent of PD-L1! Who needed that test anyway when I can
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect
Immunotherapy Advances - ASCO 2020: Key Lung Cancer Studies - Lung Cancer - 2020 ASCO Annual Meeting - Oncology - Clinical Care Options
ASCO 2020 Lung Cancer Highlights - Journal of Oncology Navigation & Survivorship
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer | NEJM
2021 Midyear Review: Non–Small-Cell Lung Cancer | Personalized Medicine in Oncology
Immunotherapy Advances - ASCO 2020: Key Lung Cancer Studies - Lung Cancer - 2020 ASCO Annual Meeting - Oncology - Clinical Care Options
Comparisons between the CheckMate 227 trial and simulation, overall... | Download Scientific Diagram
Update Confirms 5-Year Survival Benefit With Dual Immune Checkpoint Blockade in NSCLC
ASCO 2020 Lung Cancer Highlights - Journal of Oncology Navigation & Survivorship
February 6, 2018 Pivotal Phase 3 CheckMate -227 Study Demonstrates Superior Progression-Free Survival (PFS) with the Opdivo Plus
Immunotherapy in mNSCLC - ASCO 2021: Key NSCLC Studies - Lung Cancer - 2021 ASCO Virtual Annual Meeting - Health Disparities - Clinical Care Options
ESMO 2022: Treatment switching adjustment of overall survival in the CheckMate 227 clinical trial of nivolumab plus ipilimumab versus chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer
Immunotherapy in Advanced Lung Cancer
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC | Nature Reviews Clinical Oncology
Kaplan-Meier curves after matching adjustment for (A) overall survival... | Download Scientific Diagram
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial - ScienceDirect
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis - The Lancet Oncology
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update - ESMO Open
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. | Semantic
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden | NEJM
First-line Nivolumab Plus Ipilimumab is Safe
Use of Predictive Biomarkers, Incorporating Chemotherapy—What Is Best When Using Immunotherapy in Advanced NSCLC? - ILCN.org (ILCN/WCLC)
Frontiers | Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy Data for mNSCLC
New CheckMate-227 5-Year Data Show Substantial Survival Benefit of Combination Immunotherapy for Metastatic Non–Small Cell Lung Cancer
